Background. In newborns and small infants undergoing cardiac surgery with cardiopulmonary bypass (CPB) and blood priming, it is unclear whether there is reduced blood loss if fresh frozen plasma (FFP) is added to the CPB priming volume. This single-centre, randomized trial tested the hypothesis that the administration of FFP after CPB (late FFP group) is superior to FFP priming (early FFP group) in terms of postoperative bleeding and overall red blood cell (RBC) transfusion. Methods. Seventy-three infants weighing <10 kg were randomly allocated to receive FFP to supplement RBCs in the CPB priming solution (n¼36) or immediately after CPB (n¼37). The primary endpoint was a difference in postoperative blood loss; secondary endpoints included the amount of RBCs and FFP transfused through the first 48 postoperative hours. Results. All patients were included in the analysis. Patients in the late FFP arm had greater postoperative mean blood loss than patients in the early FFP arm [33.1 (SD 20.6) vs 24.1 (12.9) ml kg
cascade, and haemodilution. Despite the use of miniaturized circuits, 3 CPB still has a major impact on perioperative bleeding.
In newborns and small infants undergoing cardiac surgery, red blood cells (RBCs) are usually added to the CPB priming volume to prevent excessive haemodilution. [4] [5] [6] At the same time, maintenance of a physiologic colloid oncotic pressure during CPB must be preserved to prevent interstitial fluid accumulation; 7 8 this is achieved by adding either 5% albumin, fresh frozen plasma (FFP), or colloids to the priming. At present, few studies have investigated the superiority of FFP or albuminbased priming solutions in newborns and small infants, and the results are conflicting. [9] [10] [11] [12] [13] Potential advantages of the use of albumin in the priming solution are avoidance or limitation of exposure to allogeneic blood-derived FFP and prevention of fibrinogen adsorption and platelet adhesion to the CPB circuit and oxygenator foreign surfaces. 14 Conversely, FFP-based priming may retain a slightly higher colloid oncotic pressure and prevent the haemodilution of soluble coagulation factors and fibrinogen. To address the above-mentioned gap in knowledge, we designed a randomized trial of Albumin vs. Plasma for PaEdiAtric pRiming (APPEAR) in newborns and small (<10 kg) infants. We compared differences in coagulation and postoperative bleeding generated by the administration of FFP at different points in time (in the priming solution or at the end of CPB). Our hypothesis was that later administration of FFP is superior to its addition in the priming volume. This hypothesis was based on the assumption that by diluting soluble coagulation factors, less thrombin is generated during CPB and there is less coagulation factor consumption.
Methods
The study was approved by the local ethics committee of IRCCS San Raffaele Hospital and by the Italian Agency of Drugs. The study was registered at ClinicalTrials.gov (identifier code NCT02738190). The study was funded by research funds from IRCCS Policlinico San Donato, a clinical research hospital partially funded by the Italian Ministry of Health.
Written informed consent to participate in the study was signed by the parents of the patients.
Patient population and randomization
Inclusion criteria were planned cardiac surgery with CPB and blood priming solution and a weight <10 kg. Exclusion criteria were emergency surgery, known congenital coagulopathy, participation in another trial, or refusal to participate. The withdrawal criterion was the need for extracorporeal membrane oxygenation to wean the patient from CPB or to support them within the first 24 h from admission in the intensive care unit (ICU). A randomization code was generated with a computerized system and the patients were assigned to each group by a research doctor. The attending anaesthesiologist and the surgical staff were not blinded; conversely, ICU and ward doctors were blinded, as well as the person in charge of database data entry. ) to reach and maintain a target activated clotting time of !450 s. The CPB circuit included a hollowfibre oxygenator (Sorin KIDS D100 or D101, Livanova, Mirandola, Italy), a roller head pump (Sorin S5 HLM, Livanova), or a centrifugal pump (Bio-Medicus, Medtronic, Minneapolis, MN, USA).
Surgery and CPB

Interventions
Routine laboratory tests were performed the day before surgery, including activated partial thromboplastin time (aPTT; s), prothrombin time international normalized ratio (PT-INR), and fibrinogen levels (mg dl À1 ), plus basal haematocrit (HCT; %) and platelet count (cells Â 1000 ml À1 ). In the operating room, patients were randomly allocated to the early (bypass prime) FFP or late FFP group. After general anaesthesia induction, an arterial line was positioned and a blood sample was taken (1. Editor's key points
• Infants undergoing cardiac surgery typically need blood priming in the bypass circuit to prevent excessive haemodilution.
• Maintenance of colloid oncotic pressure during bypass is typically achieved by adding 5% albumin, fresh frozen plasma, or synthetic colloid to the priming volume.
• This study found that patients receiving early (priming volume) fresh frozen plasma had significantly less postoperative bleeding.
• Early fresh frozen plasma preserved postoperative functional fibrinogen levels.
Fresh frozen plasma priming in small infants | 789 Post-CPB bleeding was treated according to our standard protocol, which includes options for reversal of residual heparin with protamine, fibrinogen concentrate, transfusion of RBCs, platelets, and FFP. All these interventions were driven by viscoelastic tests and standard coagulation tests.
Measurements
Data collection was managed on our institutional database, which includes all the demographics, preoperative factors, procedure details, intraoperative data, and outcome measurements. For the purposes of the present study, the following parameters were measured: standard coagulation tests, including aPTT, INR, fibrinogen levels, and platelet count), and HCT was measured at four points in time: baseline, upon arrival in the ICU and 24 and 48 h after arrival in the ICU. ROTEM analysis was repeated at the same time points plus immediately after protamine administration.
Postoperative bleeding was measured at 24 h from arrival in the ICU, and transfusions were assessed separately for RBCs, FFP, and platelets during the first 48 h. The number of transfusions was assessed as a total (from CPB initiation throughout the first 48 postoperative hours) and separately at three different points: in the priming solution, from the initiation of CPB throughout surgery, and in the first 24 postoperative hours.
Study endpoints
The primary endpoint was a reduction in postoperative bleeding (ml kg À1 ) based on chest drain blood loss measured from sternal closure through the first 24 h. Severe bleeding was arbitrarily defined as a chest drain blood loss >30 ml kg À1 (roughly corresponding to the upper tertile of chest drain blood loss in our historical database). Secondary endpoints included the amount (ml kg À1 ) of allogeneic RBCs, FFP, and platelet concentrates transfused from the initiation of CPB through the first 48 postoperative hours; the length of mechanical ventilation (hours from admission in the ICU); ICU stay (days); and postoperative hospital stay (days). Our safety endpoint was the clinically determined presence of postoperative thromboembolic events.
Sample size
The sample size was based on the primary endpoint (postoperative bleeding). Historical data from the last 5 years were retrieved from the institutional database. In this population, treated with albumin 5% in the priming volume, the mean postoperative chest drain blood loss was 107 (SD 42) ml in 24 h; the effect size was assumed to be a 25% increase in bleeding rate for the FFP group (134 ml in 24 h). With a two-sided a value of 0.05 and a power of 80%, the sample size was calculated at 74 patients (37 in each arm). Considering a withdrawal rate of 5%, the number of patients to be enrolled was 80.
Statistics
Data are presented as number and percentage for dichotomous variables, mean and SD for continuous normally distributed variables, and median and interquartile range (IQR) for continuous, non-normally distributed variables. The normality of the distribution was checked with the Kolgomorov-Smirnov test. The difference in postoperative bleeding was investigated with parametric (Student's t-test) or non-parametric (Mann-Whitney U test) methods, depending on the normality assumption. Secondary endpoints were assessed using parametric or nonparametric tests for continuous variables and Pearson chisquare or Fisher exact test for dichotomous variables, producing relative risks (RRs) with 95% confidence intervals (CIs). In case of inhomogeneity of the two study arms, the use of adjustment factors was planned. Based on previous studies, 9 a subgroup analysis in cyanotic patients (defined as patients presenting arterial desaturation due to right-to-left intracardiac shunt) undergoing complex [Risk Adjusted classification for Congenital Heart Surgery (RACHS)-1 !3] surgery was planned. An additional post hoc agebased subgroup analysis was also done. All the analyses were based on the intention-to-treat principle, but excluding planned withdrawals, and performed with a computerized package (SPSS 20.0, IBM, Armonk, NY, USA). P-values <0.05 were considered significant.
Results
Patients and procedures
The general screening, enrolment, and randomization procedure is shown in Fig. 1 . The first patient was randomized on January 22, 2015, and the last on March 16, 2016. Three patients in the late FFP arm and four patients in the early FFP arm were withdrawn due to the need for extracorporeal membrane oxygenation support. All the patients received the allocated treatment. Adherence to the study protocol was 100% in both arms. The same amount of albumin 5% and FFP [40 (IQR 38-48) ml kg À1 ] was used in the late FFP and early FFP arms. The final analysis for efficacy and safety include 36 patients in the early FFP arm and 37 patients in the late FFP arm. Table 1 reports the preoperative and intra-operative profiles of the two treatment arms. No significant differences existed between study arms.
Haemostasis parameters
The standard and viscoelastic haemostasis parameters during the study period are shown in Table 2 . No significant betweengroup differences were observed with respect to aPTT, INR, and platelet count. Fibrinogen values did not significantly differ between study arms at baseline and upon arrival in the ICU; conversely, fibrinogen levels were significantly higher in the early FFP arm at the 24 h (P¼0.036) and 48 h (P¼0.030) sampling times. Values of fibrinogen <150 mg dl À1 upon arrival in the ICU were found in 5 (14%) patients in the early FFP arm and 11 (30%) patients in the late FFP arm (P¼0.102).
The clotting time at EXTEM did not differ between study arms at any point in time. The parameter of clot firmness showed significant differences between the study arms: the EXTEM MCF was significantly (P¼0.001) larger in the early FFP arm after protamine administration, but not upon arrival in the ICU or later on. The MCF at FIBTEM was significantly larger in the early FFP arm after protamine administration (P¼0.001) and upon arrival in the ICU (P¼0.038) but not at subsequent points in time. FIBTEM values <9 mm (lower limit of the normal range) were found in 15 (41.7%) patients in the early FFP group and 26 (70.3%) patients in the late FFP group (P¼0.014).
Primary endpoint
Postoperative bleeding from chest drains during the first 24 postoperative hours was significantly (P¼0.028) higher in the late FFP arm [33.1 (SD 20.6) ml kg À1 ] than in the early FFP arm
[24.1 (SD 12.9)], with a mean difference of 9 ml kg À1 (95% CI 1-19) (Fig. 2) .
Chest drain blood loss in the first 24 postoperative hours not standardized for body weight was 154 (SD 101) ml in the late FFP group and 117 (SD 52) ml in the early FFP group (P¼0.05). 
Secondary endpoints
RBC transfusion volume did not significantly differ between study arms at any time point during the first 48 h and as a total (Fig. 3) . Total FFP transfusion volume was significantly higher in the early FFP arm; due to the study design, patients in the early FFP arm received significantly more FFP in the CPB priming volume, while patients in the late FFP group received significantly more FFP from the end of CPB through arrival in the ICU (Fig. 4) 
Safety outcomes
No thromboembolic events occurred in either group. Total mortality rate was 1.4%.
Discussion
Our experimental hypothesis (superiority of late vs early FFP administration) was not confirmed by our results. Conversely, patients in the late FFP arm had significantly greater postoperative bleeding and a significantly greater rate of severe bleeding. In the overall population, the lower bleeding detected in the early FFP arm was obtained at the expense of greater use of FFP, whereas no difference was found in terms of RBC transfusions. In a subgroup of preoperatively cyanotic patients undergoing complex surgery, the bleeding tendency was confirmed in the late FFP arm and resulted in a significantly greater need for RBC transfusions. Overall, we did not observe differences in other outcomes and complication rates. To the best of our knowledge, this is the largest randomized study comparing different timing strategies for FFP administration in newborns and small infants. There are two previous randomized trials with a similar study design. In 2003, Oliver and colleagues 9 compared two groups of 28 patients weighing 10 kg and receiving 1 U of FFP or 200 ml of albumin 5% in the CPB primer. Although the overall chest drain blood loss was not significantly different between groups, patients requiring complex surgery and cyanotic patients had greater postoperative blood loss in the albumin 5% group. There was a larger amount of FFP administered in the FFP group, and no significant differences in RBC or platelet transfusions, with a similar postoperative course. After CPB, patients in the albumin group had significantly lower values of fibrinogen and longer prothrombin times. The second study was a small trial comparing two groups of 10 infants each (<8 kg) receiving either 1 U of FFP or albumin in the primer. 10 Patients in the FFP arm received significantly more FFP but less cryoprecipitate than patients in the albumin group; fibrinogen levels were significantly lower in the albumin group at the end of CPB. No differences in postoperative bleeding were detected. Other study investigated the use of FFP vs albumin or other comparators in paediatric pump priming, but in heterogeneous patient populations with larger body weight. Miao and colleagues 12 analysed 80 patients weighing 5-15 kg, randomized into two groups of 40 patients receiving either gelatines or FFP in the pump primer. Patients in the gelatine group had significantly lower postoperative fibrinogen levels (indirectly measured with functional fibrinogen assay at thromboelastography); however, no differences were found in terms of postoperative bleeding and transfusion needs. Finally, Lee and colleagues 11 randomized 123 patients (ages 1 month-16 years) to receive either albumin or FFP in the pump primer. Again, postoperative fibrinogen levels were higher in the FFP group, but no differences were found in terms of bleeding, transfusions, or other outcomes. Overall, our study and all the previous ones are concordant in finding that the early administration of FFP in the CPB primer preserves early postoperative functional fibrinogen levels. The clinical consequences of this fibrinogen preservation are different depending on the age and weight of the patient. Studies including patients weighing >10 kg did not find any difference in terms of bleeding and transfusions. 10 11 Conversely, in our trial we found a higher rate of bleeding in patients treated without FFP in the primer (early FFP arm), basically confirming the results of Oliver and colleagues, 9 and significant differences in RBC transfusions in cyanotic patients undergoing complex surgery. The link between low levels of fibrinogen and postoperative bleeding in surgery for the repair of congenital heart defects has been highlighted in previous studies. Fibrinogen concentration upon arrival in ICU following cardiac surgery in 107 paediatric patients was the best predictor of SB within a set of different coagulation tests. 15 In a retrospective study on 156 paediatric patients undergoing cardiac surgery with CPB, Faraoni and colleagues 16 found that postoperative fibrinogen levels were independently associated with postoperative bleeding, identifying cut-off values of 1.5 g litre À1 for Clauss fibrinogen concentration and FIBTEM <4 for prediction of serious bleeding. We found significantly lower values of fibrinogen concentration at FIBTEM after protamine administration and upon arrival in the ICU in patients treated with a non-FFP (albumin) primer. This result appears independent from purified fibrinogen administration, because no patient received this blood derivative before protamine administration, and between protamine administration and upon arrival in the ICU the number of patients receiving purified fibrinogen and its dose did not differ between groups. Therefore, it is possible that low values of fibrinogen may explain the greater bleeding in the late FFP group. Conversely, indirect markers of thrombin activity and fibrin generation (clotting time at ROTEM, aPTT and PT-INR) and platelet count were not significantly different between arms. The present study was not designed to address the possible use of an FFP-free strategy during and after CPB in newborns and small infants. Our results seem to refute this possibility, basically due to the low FIBTEM values detected at the end of CPB in the late FFP group. However, fibrinogen concentrate could theoretically be used to replace FFP, and this could be an interesting option for future trials. We must consider, however, that using fibrinogen concentrate in these small-sized patients has important economic implications. Given a dose of 30 mg kg À1 of fibrinogen concentrate, and a mean weight for our patients of $5 kg, each patient would need a mean amount of 150 mg of fibrinogen concentrate. This blood derivative is manufactured in 1 g vials, so there would be a mean waste of 85% of an expensive product.
Limitations
We could not measure intraoperative bleeding from the end of CPB through sternal closure, limiting our measurement to chest drain blood loss. Additionally, it is known that chest drain fluid loss may be contaminated by serum and cannot be solely attributed to blood loss in small infants (unreliability of the primary endpoint measure). However, this phenomenon becomes more evident after the first postoperative hours, and we tried to limit this confounding effect by considering chest drain fluid losses within the first 24 postoperative hours. Another limitation is that we did not compare a totally FFP-free strategy with an FFPbased strategy, but instead comparing different timings of FFP administration. Due to the relatively limited patient population, we could not address the subgroup of newborns. Another limitation is related to the lack of a direct thrombin generation measure, which would have been useful for the definition of the physiopathology underlying the difference between groups. Finally, our results are based on the application of intraoperative management of bleeding based on coagulation point-of-care tests, and the administration of blood products was based on a point-of-care-based algorithm. Therefore, our results may not be generalizable to other institutions.
Conclusion
In conclusion, our hypothesis that albumin priming with late FFP administration may be superior to FFP-based priming in newborns and small infants was not supported. Conversely, our results suggest the use of FFP in CPB primer, especially in cyanotic patients undergoing complex heart surgery and those <6 months of age.
